Skip navigation

Anti-Bribery and Anti-Corruption • Third-Party Due Diligence • Regional Transparency Initiatives

May 30-31, 2018
  • Panama City, Panama
Best Practices and Strategies for Managing and Enhancing Ethics and Compliance Programs in Latin America

Pharmaceutical, biotech and medical device companies in Latin America are stepping up to combat bribery and corruption challenges. In an era of emerging compliance risks and political unrest, it is critical that life sciences organizations develop robust and tailored third-party and distributor management programs along with continuous risk-based auditing and monitoring of third-parties. Join us this May at CBI’s PCC Latin America to strengthen compliance programs, increase transparency and commit to a culture of ethics.

Unravel the Complexities of Adhering to Local Legislation, Identifying Areas of High Risk and Enhancing Compliance Programs:

  • Regional Anti-Bribery/Anti-Corruption Legislation
    in Latin America
  • Moving Beyond Compliance —
    Integrating a Culture of Ethics into Your Organization’s DNA
  • The Evolution of Third-Party Risk Management —
    Going Beyond Contracts and Due Diligence
  • Regional Data Protection Legislation to Develop and
    Manage Effective Cybersecurity Programs
  • Effective Strategies for Managing HCP Interactions
  • Data Analytics in Auditing and Monitoring Programs
  • Best Practices for FMV Frameworks and Calculations in
    an Evolving Regulatory Landscape
  • Growing Data Privacy and Regulatory Risks
A Special Thank You to Our
Distinguished Advisory Board Members:

Rodolfo Lambour
Executive Director
Fedefarma

Gildas Durand
Principal,
Assurance Services
Ernst & Young LLP

Michael Mayes
Head of Ethics & Compliance,
Astellas International Business
Astellas

Cory LaBarge
Chief Compliance Officer,
Latin America
Grünenthal

PREVIOUS ATTENDEE ACCLAIM
FROM CBI’S PCC SERIES:

PCC Latin America

Anti-Bribery and Anti-Corruption • Third-Party Due Diligence • Regional Transparency Initiatives

Best Practices and Strategies for Managing and Enhancing Ethics and Compliance Programs in Latin America

Pharmaceutical, biotech and medical device companies in Latin America are stepping up to combat bribery and corruption challenges. In an era of emerging compliance risks and political unrest, it is critical that life sciences organizations develop robust and tailored third-party and distributor management programs along with continuous risk-based auditing and monitoring of third-parties. Join us this May at CBI’s PCC Latin America to strengthen compliance programs, increase transparency and commit to a culture of ethics.

Unravel the Complexities of Adhering to Local Legislation, Identifying Areas of High Risk and Enhancing Compliance Programs:

  • Regional Anti-Bribery/Anti-Corruption Legislation
    in Latin America
  • Moving Beyond Compliance —
    Integrating a Culture of Ethics into Your Organization’s DNA
  • The Evolution of Third-Party Risk Management —
    Going Beyond Contracts and Due Diligence
  • Regional Data Protection Legislation to Develop and
    Manage Effective Cybersecurity Programs
  • Effective Strategies for Managing HCP Interactions
  • Data Analytics in Auditing and Monitoring Programs
  • Best Practices for FMV Frameworks and Calculations in
    an Evolving Regulatory Landscape
  • Growing Data Privacy and Regulatory Risks
A Special Thank You to Our
Distinguished Advisory Board Members:

Rodolfo Lambour
Executive Director
Fedefarma

Gildas Durand
Principal,
Assurance Services
Ernst & Young LLP

Michael Mayes
Head of Ethics & Compliance,
Astellas International Business
Astellas

Cory LaBarge
Chief Compliance Officer,
Latin America
Grünenthal

PREVIOUS ATTENDEE ACCLAIM
FROM CBI’S PCC SERIES: